• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Global Medical Aesthetics Market to Reach $13 Billion by 2021 - Key Vendors are Cynosure, Syneron Medical, Allergan & Galderma - Research and Markets

    Global Medical Aesthetics Market to Reach $13 Billion by 2021 - Key Vendors are Cynosure, Syneron Medical, Allergan & Galderma - Research and Markets

  2. Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan

    Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan

  3. UPDATE: Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

    UPDATE: Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

  4. UPDATE: Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

    UPDATE: Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

  5. Valeant stock jumps 8% after positive patent litigation developments

    Valeant stock jumps 8% after positive patent litigation developments

  6. MARKET SNAPSHOT: Stock Market Closes Lower As Retail Sector Slumps, Snap's Stock Tanks

    MARKET SNAPSHOT: Stock Market Closes Lower As Retail Sector Slumps, Snap's Stock Tanks

  7. UPDATE: Stock market closes lower as retail sector slumps, Snap's stock tanks

    UPDATE: Stock market closes lower as retail sector slumps, Snap's stock tanks

  8. Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

    Weekend roundup: Good and bad company earnings | Sound investing advice | Crumbling support for Putin

  9. MARKET SNAPSHOT: U.S. Stock Futures Struggle To Gain Momentum As Fears Subside

    MARKET SNAPSHOT: U.S. Stock Futures Struggle To Gain Momentum As Fears Subside

  10. U.S. stock futures struggle to gain momentum as fears subside

    U.S. stock futures struggle to gain momentum as fears subside

12345

©2017 Morningstar Advisor. All right reserved.